News

Biogen Idec recently announced the results from a pre-specified interim analysis of PRIME, an ongoing Phase 1b randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of aducanumab (BIIB037) in patients with early or mild Alzheimer’s disease. The results were presented at the 12th International Conference…

The Innovative Medicines Initiative (IMI) together with the Global Alzheimer’s Platform (GAP) recently announced the signing of a Memorandum of Understanding (MOU) agreement based on the common goal of accelerating the search for an Alzheimer’s disease therapy through the creation of a global, standing, trial-ready platform for…

Researchers at the Rush University Medical Center, Chicago, IL and Harvard School of Public Health in Boston recently published results from an observational study that showed when a patient’s dietary intake is modified it could significantly lower their risk of developing Alzheimer’s disease (AD). The study entitled, “…

Results from the first ever randomized controlled trial of its kind shows that providing older people at risk of dementia with healthy eating assistance, brain training, exercise, and management of metabolic and vascular risk factors slows down cognitive decline. The study, entitled the Finnish Geriatric Intervention Study…

Pharmaceutical company AgeneBio recently announced the publication of results of a Phase 2 clinical trial based on the company’s therapeutic product AGB101 for the pre-dementia stage of Alzheimer’s disease in the journal NeuroImage: Clinical. The study entitled “Response of the medial temporal lobe network in…

A recently published study conducted by a team of researchers from Harvard Medical School, Boston, suggests that the currently held assumptions about the pathogenic mutation process associated with the onset of inherited or familial Alzheimer’s disease (FAD) may be inaccurate. The study entitled “Presenilin-1 Knock-in Mice Reveal…

Scientists at Australia’s University of Queensland have found that non-invasive ultrasound technology can be used to break up neurotoxic amyloid plaques that cause memory loss and cognitive decline in persons afflicted with Alzheimer’s Disease (AD), which affects more than two-thirds of dementia patients. The discovery is elucidated in a paper…

A recent study revealed that heart function is an important risk factor in the development of dementia and Alzheimer’s disease. The study entitled “Low Cardiac Index is Associated with Incident Dementia and Alzheimer’s Disease: The Framingham Heart Study” was published in Circulation by…

According to a recent study conducted by a researcher from the University of Eastern Finland, the cognitive functioning of patients with Alzheimer’s disease and their behavioral and psychological difficulties are associated with their daily living activities. However, the researchers found that deficits in cognitive performance were not associated…

According to a recent study from researchers at the Keck School of Medicine of the University of Southern California, reduced expression of a protein called GLUT1, responsible for moving glucose in the brain-blood barrier (BBB) worsens Alzheimer’s disease cerebrovascular degeneration, neuropathology and cognitive function, suggesting that GLUT1 may represent…